We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+6.6%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$117M
AUM Growth
-$70.2M
(-38%)
Cap. Flow
-$66.2M
Cap. Flow
% of AUM
-56.76%
Top 10 Holdings %
Top 10 Hldgs %
55.08%
Holding
38
New
9
Increased
1
Reduced
19
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$12.1M |
| 2 |
Axsome Therapeutics
AXSM
|
+$6.13M |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$4.54M |
| 4 |
Korro Bio
KRRO
|
+$3.63M |
| 5 |
EyePoint Inc
EYPT
|
+$3.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$8.99M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
+$8.03M |
| 3 |
Revolution Medicines
RVMD
|
+$7.41M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$6.76M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$6.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Edgewise Therapeutics
EWTX
$4.39B
| $2.22M | 1.9% |
83,176
-104,519
| -56% | -$3.33M |
|
|
SWTX
27
DELISTED
SpringWorks Therapeutics
SWTX
| $1.98M | 1.69% |
54,692
-173,008
| -76% | -$6.04M |
|
28
Context Therapeutics
CNTX
$56.4M
| $1.66M | 1.42% |
1,576,762
-180,762
| -10% | -$313K |
|
29
ProMIS Neurosciences
PMN
$109M
| $1.51M | 1.29% |
63,704
| – | – |
|
|
CLYM
30
Climb Bio
CLYM
$735M
| $1.37M | 1.17% |
760,225
-469,067
| -38% | -$1.7M |
|
|
APLT
31
DELISTED
Applied Therapeutics
APLT
| – | – |
-618,332
| Closed | -$5.26M |
|
32
Perspective Therapeutics
CATX
$332M
| – | – |
-341,739
| Closed | -$4.56M |
|
33
Disc Medicine
IRON
$2.83B
| – | – |
-100,000
| Closed | -$4.91M |
|
34
Kura Oncology
KURA
$922M
| – | – |
-294,081
| Closed | -$5.75M |
|
35
Relay Therapeutics
RLAY
$4.02B
| – | – |
-626,058
| Closed | -$4.43M |
|
|
36
Revolution Medicines
RVMD
$40.2B
| – | – |
-163,500
| Closed | -$7.41M |
|
|
37
Sarepta Therapeutics
SRPT
$1.66B
| – | – |
-72,000
| Closed | -$8.99M |
|
|
LBPH
38
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – |
-240,892
| Closed | -$8.03M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q4 2024 Portfolio in Review
As of Q4 2024, Ally Bridge Group held 38 positions worth $117M, down 38% from $187M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Ally Bridge Group withdrew a net $66.2M in Q4 2024, closing 8 positions and reducing 19 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $8.99M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Ally Bridge Group opened a new position in Intra-Cellular Therapies Inc. worth $12.3M.
- Ally Bridge Group's largest Q4 2024 buy was Intra-Cellular Therapies Inc.: 147,750 shares worth $12.3M.
- Ally Bridge Group added most to Alumis Inc in Q4 2024, an estimated $269K increase.
- Ally Bridge Group's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $6.76M.
- Ally Bridge Group fully exited Sarepta Therapeutics in Q4 2024, selling an estimated $8.99M.
- Ally Bridge Group's ten largest holdings make up 55% of its $117M portfolio in Q4 2024.
- Ally Bridge Group opened 9 new positions and closed 8 in Q4 2024.
- Ally Bridge Group's portfolio value fell 38% quarter-over-quarter to $117M.
Based on Ally Bridge Group's 13F filing for Q4 2024, filed 14 Feb 2025.